Media
Age Old Question
Published in the November edition of PharmaTimes – We’re all getting older but what can we do to halt its wicked ways? Old age. It’s something we all have in common. We either are old or, with a certain amount of fortune, we will experience it at some stage in the future. But with old age, comes trepidation.
Endometriosis: An immune disease
Published in Drug Discovery & Development – Endometriosis is a chronic incurable gynecological condition with cyclical pelvic pain, heavy bleeding, infertility, and reduced quality of life as its main manifestations. Almost half of women with it experience infertility. [1] No symptoms are specifically pathognomonic or characteristic of endometriosis. Often referred to as a ‘silent disease’ because of how often the diagnosis is missed, delayed, or dismissed, the rapid upward incidence of endometriosis since the 1980s has also led to the use of the term “silent epidemic”. [2] Approximately 10 percent of reproductive age women, or 190 million globally are impacted by it, which is no small number.
Bizzaro Cancer World
VJ Oncology
YouTube video interviews with Dr. Lucy Kennedy from Cleveland Clinic Development of AdAPT-001, a novel TGF-β-trap-enhanced oncolytic virus Phase I/II trial of AdAPT-001, an oncolytic virus, and a checkpoint inhibitor in solid tumors The future of AdAPT-001 in patients...
Targeted Oncology
Why Personalized Medicine Should Not Be Too Personalized
A licence to kill
Predicting the Abscopal Phenomenon – Letter to the Editor
Dr Tony Reid Of EpicentRx: 5 Things I Wish Someone Told Me When I First Became A Doctor
Bug in the system
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors
Age of posterity: Anti-inflammaging – a very modern dichotomy
Commentary on oncolytic viruses: past, present, and future
Tutorial on Data Management
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets
Partnering with EpicentRx
“You are only as good as the company you keep” also applies to therapeutics like AdAPT-001 – EpicentRx
Severe Oral Mucositis: Companies Put Their Money where the Mouth is and Vie for a Marketshare
A View to a Kill: Are viruses alive or dead and is it time to find out?
Therapeutic frontiers: the potential of RRx-001 and AdAPT-001
Molecule RRx-001 Receives Fast Track Designation From the FDA – EpicentRx
AdAPT-001 oncolytic adenovirus shows promising phase 1 cancer treatment results
2023 Molecule RRx-001 Receives Fast Track Designation From the FDA – EpicentRx
Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient
Profile EpicentRx, Inc
RRx-001: Jack of all trades, master of…many
EpicentRx Shares Deeper Look Into Phase 2 Data Regarding Oral Mucositis
The Case for RRx-001 as a Radiation Countermeasure
A pandemic waiting to happen: Acute radiation syndrome and the immediate need for nuclear countermeasures
Eyeing untapped niche, EpicentRx makes case for cancer toxicity prevention drug
PREVLAR: Phase 2a randomized trial to assess the safety and efficacy of RRx-001 in the attenuation of oral mucositis in patients receiving head and neck chemoradiotherapy
RRx-001 Plus Irinotecan Improves Efficacy vs Regorafenib in Colorectal Cancer
FightMND Supports ALS Research on Inflammasome Blocker RRx-001
EBOOK Drug Target Review Immuno-oncology ebook 2022
ARMED ONCOLYTIC VIRUSES – Instant Messaging Cancer With a TGF-Beta Trap Carrying Oncolytic Adenovirus
What Exactly Is Inflammation (and What Is It Not?)
Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot
Dr. Tony Reid, MD, PhD interview with Oncology Tube – REPLATINUM Phase III
The Dictatorship of Cancer: How to Topple it in Three – Not So Easy – Steps
What do dictators and the military have in common with tumors and stroma? The answer: symbiosis – a relationship in which two different types closely and intimately interact with each other to the benefit of at least one of the types. The famous phrase, “no man is an...
A next-gen vaccine that could help end COVID-19 whack-a-mole
EpicentRx used its AdAPT Platform to develop a nucleocapsid-based next-gen COVID 19 vaccine candidate and is ready for clinical trials. CEO Dr. Tony Reid recently discussed with Drug Discovery & Development.
A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)
Next-generation SARS-CoV-2 nucleocapsid-based vaccines may provide optimal protection against infection
Neuroendocrine Tumors Market to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – EpicentRx, Pfizer, Ignyta, Amgen, Progenics Pharma, Hutchison MediPharma, and Others
Clinical Catch-Up: COVID-19 Updates from Sinovac, Moderna, Arcturus, Novavax and More
EpicentRx begins Phase I trial of paediatric CNS tumour treatment
Several Players Begin 2022 with New Partnerships in Place
BioSpace
Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy
BioSpace
Epigenetic Therapies Start Operating Outside the Lines
Genetic Engineering and Biotechnology News